Myelopathies in patients with cancer

Archives of Neurology

Volumn 67, Issue 3, 2010, Pages 298-304

  Graber, Jerome J ^a   Nolan, Craig P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BETA 2 MICROGLOBULIN; BETA GLUCURONIDASE; CARCINOEMBRYONIC ANTIGEN; CARMUSTINE; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYTARABINE; DEXAMETHASONE; LACTATE DEHYDROGENASE ISOENZYME; METHOTREXATE; PROSTATE SPECIFIC ANTIGEN; SEROTONIN; STEROID; THIOTEPA;

CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DRUG MEGADOSE; EARLY DIAGNOSIS; EDEMA; EPIDURAL ABSCESS; EPSTEIN BARR VIRUS; HUMAN; HYPERBARIC OXYGEN; INCONTINENCE; INFECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PAIN; PARALYSIS; PARANEOPLASTIC NEUROPATHY; PATHOPHYSIOLOGY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION INJURY; RADIOSURGERY; REVIEW; SPINAL CORD CANCER; SPINAL CORD COMPRESSION; SPINAL CORD DISEASE; SPINAL CORD ISCHEMIA; SPINAL CORD METASTASIS; SPINAL CORD SURGERY;

CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; SPINAL CORD DISEASES;

EID: 77749310139     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.20     Document Type: Review

References (80)

1. Schiff D, O'Neill BP, Suman VJ. Spinal epidural metastases as the initial manifestation of malignancy: clinical features and diagnostic approach. Neurology. 1997;49(2):452-456.
2. Arguello F, Baggs RB, Duerst RE, Johnstone L, McQueen K, Frantz CN. Pathogenesis of vertebral metastases and epidural spinal cord compression. Cancer. 1990;65(1):98-106.
3. Kato A, Ushio Y, Hayakawa T, Yamada K, Ikeda H, Mogami H. Circulatory disturbance of the spinal cord with epidural neoplasm in rats. J Neurosurg. 1985; 63(2):260-265.
4. Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol. 1978;3(1):40-51.
5. Helweg-Larsen S, Sørensen PS. Symptoms and signs of metastatic spinal cord compression: a study of progression from first symptoms until diagnosis in 153 patients. Eur J Cancer. 1994;30A(3):396-398.
6. Li KC, Poon PY. Sensitivity and specificity of MRI in detecting malignant spinal cord compression and in distinguishing malignant from benign compression fractures of vertebrae. Magn Reson Imaging. 1988;6(5):547-556.
7. Sørensen PS, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomized trial. Eur J Cancer. 1994;30A(1):22-27.
8. Delattre JY, Arbit E, Thaler HT, Rosenblum MK, Posner JB. A dose-response study of dexamethasone in a model of spinal cord compression caused by epidural tumor. J Neurosurg. 1989;70(6):920-925.
9. Vecht CJ, Haaxma-Reiche J, van Putten WL, de Visser M, Vries EP, Twijnstra A. Initial bolus of conventional vs high-dose dexamethasone in metastatic spinal cord compression. Neurology. 1989;39(9):1255-1257.
10. Rades D, Fehlauer F, Schulte R, et al. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol. 2006;24(21):3388-3393.
11. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomized trial. Lancet. 2005;366(9486):643-648.
12. Yamada Y, Lovelock DM, Bilsky MH. A review of image-guided intensity-modulated radiotherapy for spinal tumors. Neurosurgery. 2007;61(2):226-235.
13. Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008;71(2):484-490.
14. Boogerd W, van der Sande JJ, Kröger R, Bruning PF, Somers R. Effective systemic therapy for spinal epidural metastases from breast carcinoma. Eur J Cancer Clin Oncol. 1989;25(1):149-153.
15. Wong ET, Portlock CS, O'Brien JP, DeAngelis LM. Chemosensitive epidural spinal cord disease in non-Hodgkins lymphoma. Neurology. 1996;46(6):1543-1547.
16. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SRD. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ. 2003;327(7413):469.
17. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer [update of: Cochrane Database Syst Rev. 2002;(1):CD003474]. Cochrane Database Syst Rev. 2005;(3):CD003474.
18. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev. 2006;(4):CD006250. 19. Bilsky MH. New therapeutics in spine metastases. Expert Rev Neurother. 2005; 5(6):831-840.
19. Schiff D, O'Neill BP. Intramedullary spinal cord metastases: clinical features and treatment outcome. Neurology. 1996;47(4):906-912.
20. Sutter B, Arthur A, Laurent J, et al. Treatment options and time course for intramedullary spinal cord metastasis: report of three cases and review of the literature. Neurosurg Focus. 1998;4(5):e3. doi:10.3171/foc.1998.4.5. 6.
21. Parikh S, Heron DE. Fractionated radiosurgical management of intramedullary spinal cord metastasis: a case report and review of the literature. Clin Neurol Neurosurg. 2009;111(10):858-861.
22. O'Meara WP, Borkar SA, Stambuk HE, Lymberis SC. Leptomeningeal metastasis. Curr Probl Cancer. 2007;31(6):367-424.
23. Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol. 2005;75(1):85-99.
24. Zantl N, Stein HJ, Brucher BL, Bartels H, Siewert JR. Ischemic spinal cord syndrome after transthoracic esophagectomy: two cases of a rare neurologic complication. Dis Esophagus. 2000;13(4):328-332.
25. Chapin JE, Davis LE, Kornfeld M, Mandler RN. Neurologic manifestations of intravascular lymphomatosis. Acta Neurol Scand. 1995;91(6):494-499.
26. Ormsby A, Prayson RA, Heard R. Angiotrophic large cell lymphoma mimicking multiple sclerosis associated transverse myelitis. J Clin Neurosci. 1999;6(5): 408-410.
27. Liu H, Koyanagi I, Chiba H, et al. Spinal cord infarct as the initial clinical presentation of intravascular malignant lymphomatosis. J Clin Neurosci. 2009;16 (4):570-573.
28. Heuer GG, Stiefel MF, Bailey RL, Schuster JM. Acute paraparesis from hemorrhagic spinal ependymoma: diagnostic dilemma and surgical management: report of two cases and review of the literature. J Neurosurg Spine. 2007;7(6): 652-655.
29. Howard SC, Gajjar A, Ribeiro RC, et al. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. JAMA. 2000;284 (17):2222-2224.
30. Wirtz PW, Bloem BR, van der Meer FJ, Brouwer OF. Paraparesis after lumbar puncture in a male with leukemia. Pediatr Neurol. 2000;23(1):67-68.
31. Vavricka SR, Walter RB, Irani S, Halter J, Schanz U. Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion. Ann Hematol. 2003;82(9):570-573.
32. Allen JC, Miller DC, Budzilovich GN, Epstein FJ. Brain and spinal cord hemorrhage in long-term survivors of malignant pediatric brain tumors: a possible late effect of therapy. Neurology. 1991;41(1):148-150.
33. Word JA, Kalokhe P, Aron BS, Elson HR. Transient radiation myelopathy (Lhermitte's sign) in patients with Hodgkin's disease treated by mantle irradiation. Int J Radiat Oncol Biol Phys. 1980;6(12):1731-1733.
34. Fein DA, Marcus RB Jr, Parsons JT, Mendenhall WM, Million RR. Lhermitte's sign incidence and treatment variables influencing risk after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 1993;27(5):1029-1033.
35. Uchida K, Nakajima H, Takamura T, et al. Neurological improvement associated with resolution of irradiation-induced myelopathy: serial magnetic resonance imaging and positron emission tomography findings. J Neuroimaging. 2009; 19(3):274-276.
36. Angibaud G, Ducasse JL, Baille G, Clanet M. Potential value of hyperbaric oxygen in the treatment of post-radiation myelopathies [in French]. Rev Neurol (Paris). 1995;151(11):661-666.
37. Watterson J, Toogood I, Nieder M, et al. Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer. 1994;74(11):3034-3041.
38. Counsel P, Khangure M. Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings. Clin Radiol. 2007;62(2):172-176.
39. Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg. 1997;87(5):694-699.
40. Gutin PH, Levi JA, Wiernik PH, Walker MD. Treatment of malignant meningeal disease with intrathecal thiotepa: a phase II study. Cancer Treat Rep. 1977; 61(5):885-887.
41. Wang MY, Arnold AC, Vinters HV, Glasgow BJ. Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. Am J Ophthalmol. 2000;130(3):367-368.
42. Nakagawa M, Nakamura A, Kubota R, et al. Necrotizing myelopathy associated with malignancy caused by herpes simplex virus 2: clinical report of two cases and literature review. Jpn J Med. 1991;30(2):182-188.
43. Schvoerer E, Frechin V, Fritsch S, et al. Atypical symptoms in patients with herpesvirus DNA detected by PCR in cerebrospinal fluid. J Clin Virol. 2006;35 (4):458-462.
44. Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K. Post-transplant lymphoproliferative disease and other Epstein-Barr virus disease in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis. 2007;39(3):235-244.
45. Devinsky O, Cho ES, Petito CK, Price RW. Herpes zoster myelitis. Brain. 1991;114 (pt 3):1181-1196.
46. Gilden D. Varicella zoster virus and central nervous system syndromes. Herpes. 2004;11(suppl 2):89A-94A.
47. Koeppen AH, Lansing LS, Peng SK, Smith RS. Central nervous system vasculitis in cytomegalovirus infection. J Neurol Sci. 1981;51(3):395-410.
48. Anduze-Faris BM, Fillet AM, Gozlan J, et al. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. AIDS. 2000;14(5):517-524.
49. Takeda S, Yamazaki K, Miyakawa T, Takahashi H, Ikuta F, Arai H. Progressive multifocal leukoencephalopathy showing extensive spinal cord involvement in a patient with lymphopenia. Neuropathology. 2009;29(4):485-493.
50. Majid A, Galetta SL, Sweeney CJ, et al. Epstein-Barr virus myeloradiculitis and encephalomyeloradiculitis. Brain. 2002;125(pt 1):159-165.
51. Kamin SS, Petito CK. Idiopathic myelopathies with white matter vacuolation in non-acquired immunodeficiency syndrome patients. Hum Pathol. 1991;22 (8):816-824.
52. Gonçalves DU, Felipe L, Carneiro-Proietti AB, Guedes AC, Martins-Filho OA, Lambertucci AR. Myelopathy and adult T-cell leukemia associated with HTLV-1 in a young patient with hearing loss as the initial manifestation of disease. Rev Soc Bras Med Trop. 2009;42(3):336-337.
53. Chan YC, Dasey N. Iatrogenic spinal epidural abscess. Acta Chir Belg. 2007;107 (2):109-118.
54. Babu R, Jafar JJ, Huang PP, Budzilovich GN, Ransohoff J. Intramedullary abscess associated with spinal cord ependymoma: case report. Neurosurgery. 1992; 30(1):121-124.
55. Lewis DW, Packer RJ, Raney B, Rak IW, Belasco J, Lange B. Incidence, presentation and outcome of spinal cord disease in children with systemic cancer. Pediatrics. 1986;78(3):438-443.
56. Koh S, Ross LA, Gilles FH, Nelson MD Jr, Mitchell WG. Myelopathy resulting from invasive aspergillosis. Pediatr Neurol. 1998;19(2):135-138.
57. Marra CM. Neurosyphilis. Curr Neurol Neurosci Rep. 2004;4(6):435-440.
58. Yeshurun M, Laporte JP, Lesage S, Najman A. Spinal cord compression of dual etiology, multiple myeloma and spinal tuberculosis. Leuk Lymphoma. 2002; 43(2):427-428.
59. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine (Baltimore). 1992;71(2):59-72.
60. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49(2):146-154.
61. Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003;54(1):38-50.
62. Pittock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol. 2008;65(5):629-632.
63. Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58(1):96-107.
64. Pittock SJ, Yoshikawa H, Ahlskog JE, et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal and spinal cord dysfunction. Mayo Clin Proc. 2006;81(9):1207-1214.
65. Leypoldt F, Eichhorn P, Saager C, Munchau A, Lewerenz J. Successful immunosuppressive treatment and long-term follow-up of anti-Ri-associated paraneoplastic myelitis. J Neurol Neurosurg Psychiatry. 2006;77(10):1199-1200.
66. Drobyski WR, Potluri J, Sauer D, Gottschall JL. Autoimmune hemolytic anemia following T-cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996;17(6):1093-1099.
67. Richard S, Fruchtman S, Scigliano E, Skerrett D, Najfeld V, Isola L. An immunologic syndrome featuring transverse myelitis, Evan's syndrome and pulmonary infiltrates after unrelated bone marrow transplant in a patient with severe aplastic anemia. Bone Marrow Transplant. 2000;26(11):1225-1228.
68. Pérez-Montes R, Richard C, Baro J, Pascual J, Varela R, Zubizarreta A. Acute transverse myelitis and autoimmune pancytopenia after unrelated hematopoietic cell transplantation. Haematologica. 2001;86(5):556-557.
69. Kuroda Y, Miyahara M, Sakemi T, et al. Autopsy report of acute necrotizing opticomyelopathy associated with thyroid cancer. J Neurol Sci. 1993;120(1): 29-32.
70. Okai AF, Muppidi S, Bagla R, Leist TP. Progressive necrotizing myelopathy: part of the spectrum of neuromyelitis optica? Neurol Res. 2006;28(3):354-359.
71. Darnell RB, Victor J, Rubin M, Clouston P, Plum F. A novel antineuronal antibody in stiff-man syndrome. Neurology. 1993;43(1):114-120.
72. Butler MH, Hayashi A, Ohkoshi N, et al. Autoimmunity to gephyrin in stiff-man syndrome. Neuron. 2000;26(2):307-312.
73. McCabe DJH, Turner NC, Chao D, et al. Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies. Neurology. 2004;62 (8):1402-1404.
74. Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology. 2008;71(24):1955-1958.
75. Sanders KA, Rowland LP, Murphy PL, et al. Motor neuron diseases and amyotrophic lateral sclerosis: GM1 antibodies and paraproteinemia. Neurology. 1993; 43(2):418-420.
76. Verma A, Berger JR, Snodgrass S, Petito C. Motor neuron disease: a paraneoplastic process associated with anti-Hu antibody and small cell lung carcinoma. Ann Neurol. 1996;40(1):112-116.
77. Berghs S, Ferracci F, Maksimova E, et al. Autoimmunity to βIV spectrin in paraneoplastic lower motor neuron syndrome. Proc Natl Acad Sci U S A. 2001; 98(12):6945-6950.
78. Waragai M, Chiba A, Uchibori A, Fukushima T, Anno M, Tanaka K. Anti-Ma2 associated paraneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy. J Neurol Neurosurg Psychiatry. 2006;77(1): 111-113.
79. Gordon PH, Rowland LP, Younger DS, et al. Lymphoproliferative disorders and motor neuron disease: an update. Neurology. 1997;48(6):1671-1678.
80. Forman D, Rae-Grant AD, Matchett SC, Cowen JS. A reversible cause of hypercapnic respiratory failure: lower motor neuronopathy associated with renal cell carcinoma. Chest. 1999;115(3):899-901.